Real-World Outcomes for Patients with HCC Receiving Lenvatinib After IO

Amit Mahipal, MD, University Hospitals Seidman Cancer Center, and Richard S. Finn, MD, University of California, Los Angeles, discuss a recent study on real-world outcomes for patients with advanced hepatocellular carcinoma receiving lenvatinib following immunotherapy.


DocWire Content Partners

Powered by DocWire News

The Latest From GI Oncology Now

The Latest From Heme Today

Expert Interviews